drugset
drugset / Trial / NCT04567303

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT04567303 ↗

Phase 1/2 Active not recruiting 177 enrolled Hoffmann-La Roche
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).

Timeline

Start
2020-10-28
Primary completion
2026-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 100 mg/ml Other
Subject Zifibancimig Monoclonal antibody — Intravitreal

Indications

macular degeneration